Gene expression profiling in a retrospective real-world cohort of breast cancer brain metastases and paired primary tumors identifies biological changes with potential therapeutic implications
Gaia Griguolo(University of North Carolina at Chapel Hill), V. Guarneri(Istituto Oncologico Veneto), Luc Bauchet(Hôpital Gui de Chauliac), Angelo Paolo Dei Tos(University of Padua), Jack Jacob(Alaska Women's Cancer Care), Claudia Pinato(Istituto Oncologico Veneto), Susan Fineberg(Albert Einstein College of Medicine), Matteo Fassan(University of Padua), Amélie Darlix(Institut de Recherche en Cancérologie de Montpellier), Francesca Zanconato(University of Padua), William Jacot(Inserm), Valérie Rigau(Université de Montpellier), Michele Bottosso(University of Padua), Maria Vittoria Dieci(Istituto Oncologico Veneto), M.C. Guarascio(University of Padua), Francesca Schiavi(Istituto Oncologico Veneto), Federica Miglietta(University of Padua)
Cited by 3
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k